HippoFi
-
Biologics
HippoFi Announces Its Return to a Pink Current Information Tier on the OTC Market
IRVINE, CA., April 12, 2023 /OrthoSpineNews/ – HippoFi, Inc. (OTC Pink: ORHB), a diversified company focused on the biotech and…
Read More » -
Biologics
PUR Biologics Announces Launch of PURcore™, a bioActive Moldable Synthetic for Spine Surgery
IRVINE, CA., April 6, 2023 /OrthoSpineNews/ – PUR Biologics, a subsidiary of HippoFi, Inc. (OTC Pink: ORHB), is proud to…
Read More » -
Biologics
HippoFi Begins 2023 with Strong Sales of Advanced Biomaterials
Expanded sales force fuels market growth. IRVINE, CA., January 13, 2023 /OrthoSpineNews/ – HippoFi, Inc. (formerly ORHub), (OTC Pink: ORHB),…
Read More » -
Spine
HippoFi’s Regenerative Therapeutics Division Launches PURbridge™ for Spine Surgery
PURbridge™, an advanced synthetic and new form of bioactive glass, is positioned to significantly increase the Company’s revenue throughout 2023…
Read More » -
Biologics
HippoFi Signs Strategic Partnership Agreement With Precision Spine, Inc.
“HippoFi accesses Precision Spine’s major sales channels to speed its sales strategy & quickly drive revenue” IRVINE, CA, October 5, 2022,…
Read More » -
Shareholder Letter from Founder, Executive Chairman & CEO CJ Wiggins regarding HippoFi®
September 7, 2022 – OrthoSpineNews- Dear Shareholders, I am writing to you, to share our team’s accomplishments over the last…
Read More » -
Hospitals
ORHub Adopts New Name to Reflect its FinTech Future – “HippoFi”
Born from ORHub®, HippoFiTM represents the company’s fintech focuswith commitment to the ‘Hippocratic Oath’ and patient clinical improvements. IRVINE, CA, August…
Read More »